Gut microbiota as a predictive tool for outcomes in IgA nephropathy

Area of Science:

• Nephrology
• Microbiology
• Gastroenterology

Background:

• Immunoglobulin A nephropathy (IgAN) involves glomerular IgA1 deposition and is linked to the gut-kidney axis.
• Gut microbiota dysbiosis is increasingly implicated in IgAN pathogenesis and progression.

Purpose of the Study:

• To investigate if baseline gut microbiota composition can predict therapeutic response in IgAN patients.
• To identify specific microbial signatures associated with treatment outcomes in IgAN.

Main Methods:

• Fecal samples from 55 biopsy-confirmed IgAN patients were analyzed using 16S rRNA sequencing.
• Patients were categorized as responders (n=39) or nonresponders (n=16) based on remission status over 6 months.
• A predictive classifier was developed using amplicon sequence variants to identify nonresponders.

Main Results:

• Significant differences in gut microbiota were observed between responders and nonresponders.
• Nonresponders exhibited higher levels of Proteobacteria and Firmicutes, including opportunistic pathogens like Escherichia-Shigella and Pseudomonas.
• A classifier based on 24 ASVs, notably Escherichia-Shigella and Pseudomonas, accurately predicted nonresponders (AUC 0.9103, p < 0.0001).

Conclusions:

• Baseline gut microbial dysbiosis is associated with poor therapeutic response in IgAN.
• Gut microbiota profiling may serve as a predictive biomarker for IgAN treatment outcomes.
• Targeting the gut microbiome could offer a novel strategy for personalized IgAN management.